Literature DB >> 8109837

Rapamycin inhibits p34cdc2 expression and arrests T lymphocyte proliferation at the G1/S transition.

W M Flanagan1, G R Crabtree.   

Abstract

Rapamycin, a potent immunosuppressant and antifungal agent, inhibits an evolutionarily conserved mechanism regulating cell cycle progression. In an interleukin-2 (IL-2) dependent murine T cell, we demonstrate that rapamycin arrested T cells prior to the entry into S-phase of the cell cycle and that rapamycin inhibited the IL-2-stimulated expression of p34cdc2, a serine/threonine kinase that is required for cells to progress through the cell cycle. The mechanism of action of rapamycin appeared specific since the structural analogue and immunosuppressant FK506 had no effect on the progression of the cells through S-phase or the expression of p34cdc2. These results demonstrate a rapamycin-sensitive IL-2-dependent signaling pathway in T cells and suggest that the immunosuppressive properties of rapamycin are mediated by impinging on the IL-2-induced T cell expression of p34cdc2.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8109837     DOI: 10.1111/j.1749-6632.1993.tb17139.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

Review 1.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 2.  New immunosuppressive drugs: mechanistic insights and potential therapeutic advances.

Authors:  A W Thomson; T E Starzl
Journal:  Immunol Rev       Date:  1993-12       Impact factor: 12.988

Review 3.  Therapeutic advances in immunosuppression.

Authors:  A W Thomson; J V Forrester
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

4.  An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation.

Authors:  G I Kovalev; D S Franklin; V M Coffield; Y Xiong; L Su
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

5.  The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.

Authors:  M Majewski; M Korecka; P Kossev; S Li; J Goldman; J Moore; L E Silberstein; P C Nowell; W Schuler; L M Shaw; M A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.